J&J Challenges Risperdal Penalty As First Amendment Violation
This article was originally published in The Pink Sheet Daily
In case that could impact use of state unfair trade practices statutes, Janssen seeks Supreme Court review of South Carolina’s $124 million judgment for Risperdal labeling and Dear Doctor letter.
You may also be interested in...
US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.
J&J’s agreement with state AGs, which involves payments totaling $181 million, sets a number of restrictions on the company’s marketing practices for atypical antipsychotics that will be in effect for five years.